Welcome to Markets Desk, your midday read on what's moving and why.
Citigroup is pulling back from one of its marquee calls on big tech, abandoning a hyperscaler trade that's been caught in a sharp sector rotation. Growth and mega-cap names have underperformed as money moves into more defensive corners of the market, and Citi's retreat signals that conviction in that crowded trade is fading fast.
Elsewhere in the analyst community, Artelo Biosciences is drawing attention after its consensus price target was revised to eight hundred twenty-six dollars and twenty cents per share, a staggering increase of twenty-six hundred percent from a prior estimate of thirty dollars and sixty cents. Moves of that magnitude in a small-cap biotech name warrant scrutiny — a single initiating analyst can swing aggregate targets dramatically, and investors should weigh that context carefully before reading too much into the headline.
On a more measured note, Bankwell Financial Group saw its consensus price target lifted roughly twenty-four percent to seventy-seven dollars and fifty-two cents, up from sixty-two dollars and seventy-three cents. Regional bank upgrades have been quietly accumulating as the rate environment stabilizes, and Bankwell's revised target fits that broader pattern of renewed confidence in community lenders.
That's the tape. Markets Desk, signing off the floor.
